Although these results demonstrate that tumor-specific genetic depletion of USP8 could significantly enhance the therapeutic efficacy of PD-L1 blockade, the systemically using USP8 inhibitor treatment may also affect the function of other cells including immune cells in vivo. Here, USP8 is linked to neoplasm.